Livistona chinensis seeds inhibit hepatocellular carcinoma angiogenesis in vivo via suppression of the Notch pathway

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1723-1728

  Lin, Wei ^a   Zhao, Jinyan ^a   Cao, Zhiyun ^a   Zhuang, Qunchuan ^a   Zheng, Liangpu ^a   Zeng, Jianwei ^a   Hong, Zhenfeng ^a   Peng, Jun ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Herbal medicine; Livistona chinensis seeds; Notch pathway

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; DLL4 PROTEIN; JAGGED1; LIVISTONA CHINENSIS EXTRACT; NOTCH RECEPTOR; PEPTIDES AND PROTEINS; PLANT EXTRACT; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARECACEAE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVISTONA CHINENSIS; MALE; MOUSE; NONHUMAN; PLANT SEED; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; ARECACEAE; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTORS, NOTCH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEEDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908134996     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3051     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M and Broelsch CE: Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 205: 27-36, 2007.
3. Gish RG and Baron A: Hepatocellular carcinoma (HCC): current and evolving therapies. IDrugs 11: 198-203, 2008.
4. Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol 9: 767-776, 2007.
5. Jia L: Cancer complementary and alternative medicine research at the US National Cancer Institute. Chin J Integr Med 18: 325-332, 2012.
6. Carmady B and Smith CA: Use of Chinese medicine by cancer patients: a review of surveys. Chin Med 9: 22, 2011.
7. Cheueng S and Tai J: In vitro studies of the dry fruit of Chinese fan palm Livistona chinensis. Oncol Rep 5: 1331-1336, 2005.
8. Sartippour MR, Liu C and Shao ZM: Livistona extract inhibits angiogenesis and cancer growth. Oncol Rep 6: 1355-1357, 2001.
9. Huang WC, Hsu RM, Chi LM, et al: Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown. Cancer Lett 248: 137-146, 2007.
10. Wang H, Li A, Dong XP and Xu XY: Screening of anti-tumor parts from the seeds of Livistona chinensis and its anti-angiogenesis effect. Zhong Yao Cai 31: 718-722, 2008 (In Chinese).
11. Lin W, Zhao J, Cao Z, Zhuang Q, Zheng L, Cai Q, Chen D, Wang L, Hong Z and Peng J: Livistona chinensis seed suppresses hepatocellular carcinoma growth through promotion of mitochondrial-dependent apoptosis. Oncol Rep 29: 1859-1866, 2013.
12. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
13. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
14. Schneider BP and Miller KD: Angiogenesis of breast cancer. J Clin Oncol 23: 1782-1790, 2005.
15. Uzzan B, Nicolas P, Cucherat M and Perret GY: Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64: 2941-2955, 2004.
16. Weidner N: The importance of tumor angiogenesis: the evidence continues to grow. Am J Clin Pathol 122: 675-677, 2004.
17. Kut C, Mac Gabhann F and Popel AS: Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97: 978-985, 2007.
18. Takeshita K, Satoh M, Ii M, Silver M, Limbourg FP, Mukai Y, Rikitake Y, Radtke F, Gridley T, Losordo DW and Liao JK: Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res 100: 70-78, 2007.
19. Garcia A and Kandel JJ: Notch: a key regulator of tumor angiogenesis and metastasis. Histol Histopathol 27: 151-156, 2012.
20. Dufraine J, Funahashi Y and Kitajewski J: Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27: 5132-5137, 2008.
21. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G and Yan M: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083-1087, 2006.
22. Miele L, Golde T and Osborne B: Notch signaling in cancer. Curr Mol Med 6: 905-918, 2006.
23. Yanagawa S, Lee JS, Kakimi K, Matsuda Y, Honjo T and Ishimoto A: Identification of Notch1 as a frequent target for provirus insertional mutagenesis in T-cell lymphomas induced by leukemogenic mutants of mouse mammary tumor virus. J Virol 74: 9786-9791, 2000.
24. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD and Sklar J: TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661, 1991.
25. Sjölund J, Manetopoulos C, Stockhausen MT and Axelson H: The Notch pathway in cancer: differentiation gone awry. Eur J Cancer 41: 2620-2629, 2005.
26. Nijjar SS, Crosby HA, Wallace L, Hubscher SG and Strain AJ: Notch receptor expression in adult human liver: a possible role in bile duct formation and hepatic neovascularization. Hepatology 34: 1184-1192, 2001.
27. Nijjar SS, Wallace L, Crosby HA, Hubscher SG and Strain AJ: Altered Notch ligand expression in human liver disease: further evidence for a role of the Notch signaling pathway in hepatic neovascularization and biliary ductular defects. Am J Pathol 160: 1695-1703, 2002.
28. Dorrell MI, Aguilar E, Scheppke L, Barnett FH and Friedlander M: Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 104: 967-972, 2007.
29. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
30. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
31. Folkman J: Angiogenesis. Annu Rev Med 57: 1-18, 2006.
32. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
33. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
34. Jain RK: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29 (Suppl 16): 3-9, 2002.
35. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29 (Suppl 16): 10-14, 2002.
36. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T and Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863, 1996.
37. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F and Ishii S: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577, 2000.
38. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
39. Purow B: Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol 727: 305-319, 2012.
40. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G and Yancopoulos GD: Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA 101: 15949-15954, 2004.
41. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L, Henrique D and Rossant J: Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev 18: 2474-2478, 2004.
42. Skrtic A, Sokolic L, Borovecki A, Rosa J and Fenzl V: Immunohistochemical localization of CD31, NOTCH1 and JAGGED1 proteins in experimentally induced polycystic ovaries of immature rats. Acta Histochem 113: 262-269, 2011.
43. Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M and Adams RH: The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137: 1124-1135, 2009.